PMID- 26117009
OWN - NLM
STAT- MEDLINE
DCOM- 20151124
LR  - 20181023
IS  - 1009-2137 (Print)
IS  - 1009-2137 (Linking)
VI  - 23
IP  - 3
DP  - 2015 Jun
TI  - [Prognostic Value of Prednisone Response in CCLG-ALL 2008].
PG  - 642-6
LID - 10.7534/j.issn.1009-2137.2015.03.008 [doi]
AB  - OBJECTIVE: To ovaluate the prognostic value of prednisone response in treatment 
      regimes of children with acute lymphoblastic leukemia. METHODS: A total of 598 
      newly diagnosed ALL patients were enrolled and received prednisone pre-treatment. 
      Based on the peripheral lymphoblast count on day 8, these patients were divided 
      into 2 groups: prednisone good response (PGR) and prednisone poor response (PPR). 
      PPR patients were classified into high risk group immediately and then received 
      intensed chemotherapy. The all enrolled patients were followed up and the 
      clinical features and treatment outcomes of the two groups were analyzed. 
      RESULTS: Compared with PGR group, PPR group had different characteristics. They 
      were older in age and had higher initial white blood cell count (P<0.05). T-cell 
      ALL (T-ALL) and Philadelphia chromosome positive ALL (Ph+ ALL) were frequent in 
      PPR group (P<0.05). Event-free survival (EFS) rate of PPR group was significantly 
      lower than that of PGR group (P<0.05). 2 year event-free survival(EFS) rate of 
      PGR group was (88.3+/-1.5)%, while the 2-year EFS rate of PPR group was 
      (58.4+/-5.3)%. 5 year EFS rates of PGR and PPR were (80.8+/-2.1)% and (53.4+/-6.0)%, 
      respectively. The EFS rate of PPR group was falling rapidly within 2 years. PPR 
      group had higher relapse rate, and most relapses occurred within 18 months 
      (P<0.05). PPR group had more high incidence of minimal residual disease (MRD) 
      both on day 33 and on week 12 (P<0.05). No significant difference of EFS and 
      relapse time was found between PPR and high risk PGR patients (P>0.05). In 
      multi-variate regression analysis, the PPR, the presence of BCR-ABL1 and MLL were 
      significantly unfavorable factors (P<0.05). CONCLUSION: Prednisone response has 
      been confirmed to be still great prognostic value and PPR children patients have 
      poor outcomes generally. It is likely that the response to prednisone does not 
      make much sense to high risk ALL patients.
FAU - Ren, Yuan-Yuan
AU  - Ren YY
AD  - Institute of Hematology & Hospital of Blood Disease, Chinese Academy of Medical 
      Science & Peking Union Medical College, Tianjin 300020, China.
FAU - Zou, Yao
AU  - Zou Y
AD  - Institute of Hematology & Hospital of Blood Disease, Chinese Academy of Medical 
      Science & Peking Union Medical College, Tianjin 300020, China.
FAU - Chang, Li-Xian
AU  - Chang LX
AD  - Institute of Hematology & Hospital of Blood Disease, Chinese Academy of Medical 
      Science & Peking Union Medical College, Tianjin 300020, China.
FAU - An, Wen-Bin
AU  - An WB
AD  - Institute of Hematology & Hospital of Blood Disease, Chinese Academy of Medical 
      Science & Peking Union Medical College, Tianjin 300020, China.
FAU - Wan, Yang
AU  - Wan Y
AD  - Institute of Hematology & Hospital of Blood Disease, Chinese Academy of Medical 
      Science & Peking Union Medical College, Tianjin 300020, China.
FAU - Zhang, Jing-Liao
AU  - Zhang JL
AD  - Institute of Hematology & Hospital of Blood Disease, Chinese Academy of Medical 
      Science & Peking Union Medical College, Tianjin 300020, China.
FAU - Liu, Tian-Feng
AU  - Liu TF
AD  - Institute of Hematology & Hospital of Blood Disease, Chinese Academy of Medical 
      Science & Peking Union Medical College, Tianjin 300020, China.
FAU - Zhu, Xiao-Fan
AU  - Zhu XF
AD  - Institute of Hematology & Hospital of Blood Disease, Chinese Academy of Medical 
      Science & Peking Union Medical College, Tianjin 300020, China. E-mail: 
      xfzhu1981@126.com.
LA  - chi
PT  - English Abstract
PT  - Journal Article
PL  - China
TA  - Zhongguo Shi Yan Xue Ye Xue Za Zhi
JT  - Zhongguo shi yan xue ye xue za zhi
JID - 101084424
RN  - VB0R961HZT (Prednisone)
SB  - IM
MH  - Disease-Free Survival
MH  - Humans
MH  - Multivariate Analysis
MH  - Neoplasm, Residual
MH  - *Precursor Cell Lymphoblastic Leukemia-Lymphoma
MH  - Prednisone
MH  - Prognosis
MH  - Recurrence
MH  - Treatment Outcome
EDAT- 2015/06/29 06:00
MHDA- 2015/12/15 06:00
CRDT- 2015/06/29 06:00
PHST- 2015/06/29 06:00 [entrez]
PHST- 2015/06/29 06:00 [pubmed]
PHST- 2015/12/15 06:00 [medline]
AID - 1009-2137(2015)03-0642-05 [pii]
AID - 10.7534/j.issn.1009-2137.2015.03.008 [doi]
PST - ppublish
SO  - Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2015 Jun;23(3):642-6. doi: 
      10.7534/j.issn.1009-2137.2015.03.008.